{
    "nct_id": "NCT05361720",
    "official_title": "Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)",
    "inclusion_criteria": "* Histological confirmation of RCC with a clear cell component\n* Advanced (not amenable to curative surgery or radiation therapy) or metastatic (American Joint Committee on Cancer [AJCC] stage IV) RCC\n* Patient can comprehend and sign the study informed consent form\n* Male or female >= 18 years of age at the time of informed consent\n* Karnofsky performance status (KPS) of >= 70%\n* No prior systemic therapy for RCC in the neoadjuvant, adjuvant or metastatic setting\n* At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* Tumor tissue for ribonucleic acid (RNA)-sequencing (tumor tissue from bony metastasis is not suitable but a soft tissue component around bone is acceptable)\n\n  * Screening tissue consent- Patient must be assigned to either Cluster 1/2 or 4/5. Patients assigned to cluster 3/6/7 will not be eligible for the treatment study\n* Adequate renal function defined as calculated creatinine clearance >= 30 mL/min per the Cockcroft and Gault formula\n* Adequate liver function defined by:\n\n  * Total bilirubin =< 1.5 times the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN\n* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test during screening and prior to receiving first dose of protocol-indicated treatment\n\n  * Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or is not postmenopausal\n  * Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 years of age in the absence of other biological or physiological causes\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* =< 14 days before first dose of protocol-indicated treatment:\n\n  * Major surgery requiring general anesthesia\n* Inadequately controlled hypertension (systolic blood pressure [SBP] > 160/90 mmHg)\n\n  * Anti-hypertensive medications are permitted.\n* Active infection requiring infusional treatment\n* Has preexisting gastrointestinal or non-gastrointestinal fistula\n* Proteinuria > 2 g/ 24 hours (hrs)\n\n  * If patient has 1+ protein on urine dipstick then a 24 hr urine collection is required\n* Non-healing wounds on any part of the body (for patients assigned to Cabo/Nivo only)\n* Known clinically significant active bleeding including hemoptysis\n* Inability to swallow oral medication; or the presence of a poorly controlled gastrointestinal disorder that could significantly affect the absorption of oral study drug (for patients assigned to Cabo/Nivo only) - e.g., Crohn's disease, ulcerative colitis, chronic diarrhea (defined as > 4 loose stools per day), malabsorption, or bowel obstruction\n* Significant cardiovascular disease or condition including:\n\n  * Class III or IV cardiovascular disease according to the New York Heart Association (NYHA) functional criteria\n  * Unstable angina pectoris (i.e., last episode =< 3 months prior to first dose of protocol-indicated treatment)\n  * Myocardial infarction within 3 months prior to starting treatment\n* Subjects with central nervous system (CNS) metastases are eligible after they have completed local therapy (e.g., whole brain radiation therapy [WBRT], surgery or radiosurgery)\n* Any condition requiring systemic treatment with either systemic corticosteroids (> 10 mg/day prednisone or equivalent daily) or other immunosuppressive medications within 14 days prior to initiating protocol-indicated treatment\n* In the absence of active autoimmune disease: Subjects are permitted the use of corticosteroids with minimal systemic absorption (e.g., topical, ocular, intra-articular, intranasal, and inhalational), =< 10 mg/day prednisone or equivalent daily; and physiologic replacement doses of systemic corticosteroids =< 10 mg/day prednisone or equivalent daily (e.g., hormone replacement therapy needed in patients with hypophysitis)",
    "miscellaneous_criteria": ""
}